Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellectis Announced Collaboration Agreement with Stemgent

Published: Monday, March 11, 2013
Last Updated: Sunday, March 10, 2013
Bookmark and Share
Agreement to provide custom genome-engineered iPS cells.

Cellectis Bioresearch has announced a collaboration agreement with Stemgent, Inc. to provide research services that combines mRNA reprogramming technology and genome engineering.

The partnership marries Cellectis bioresearch’s leadership in genome engineering with Stemgent’s expertise in cellular reprogramming.

Stemgent’s proprietary mRNA reprogramming technology addresses the challenges around deriving non-viral non-integrating clinically-relevant induced pluripotent stem (iPS) cells for use in regenerative medicine drug discovery and basic research.

Traditional reprogramming methods can lead to the integration of unwanted genetic material into the host genome and therefore can be disruptive to the reprogrammed cell’s function.

Targeted genome engineering is a powerful technology that can be used to elucidate the genetic basis of diseases and to evaluate drug candidates through the generation of cell-based assays.

Cellectis bioresearch’s TALEN™-based genome engineering technology enables the directed introduction of disease-specific genetic mutations to mimic disease and of reporter genes with fluorescent/luminescent tags to evaluate drug candidate efficacy specificity and toxicity.

Together these two powerful technologies pave the way for clinically-relevant applications in regenerative medicine.

Cellectis Group CEO André Choulika said “The collaboration between Stemgent and Cellectis fits with our mission to enable scientists worldwide with the tools to generate genome-engineered iPS cells for use in their research and regenerative medicine.”

“Drug toxicity testing is an important part of early-stage drug development continued Ian Ratcliffe Stemgent President and CEO. “The challenge researchers face is that current models to test drugs are often inadequate. With this partnership and the combined technologies we can introduce mutations into reprogrammed cells and differentiate them into downstream lineages. Researchers can utilize these cells to test how mutations known and unknown alter the biology of the cells upon exposure to drugs.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Epigenetic Clock Predicts Life Expectancy
New research finds 5 percent of population ages faster, faces shorter lifespan.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!